Advertising in Research Reviews Journal of Oncology and Hematology: Rates, Formats, and Why It Works for Medical Brands in India

Most pharmaceutical marketing teams we speak with are surprised to learn that a single full-page insertion in a well-indexed oncology journal can put a brand in front of a more qualified, decision-ready audience than a month-long digital campaign costing three times as much. The Research Reviews Journal of Oncology and Hematology — published by STM Journals under the CELNET umbrella — is one of those properties that consistently underperforms its own potential simply because brands do not know enough about it to book confidently. We wrote this guide to change that.

What Is Research & Reviews: Journal of Oncology and Hematology?

There is a tendency in media planning circles to treat all medical journals as interchangeable, which is a mistake that costs brands both money and relevance. Research & Reviews: Journal of Oncology and Hematology — commonly referred to as RRJoOH — is a peer-reviewed, open access journal published by STM Journals, which is the publishing arm of CELNET (Consortium e-Learning Network Pvt. Ltd.), a Noida, India-based academic publishing house with a significant footprint in the scientific, technical, and medical publishing segment. What distinguishes RRJoOH from general medical publications is its editorial focus: the journal covers clinical oncology, hematology, radiation oncology, surgical oncology, medical oncology, pediatric oncology, hematopoiesis, thrombosis and vascular biology, and cell therapy — which means every reader who picks up an issue is there specifically because oncology and hematology are central to their professional practice.

The journal is published on a tri-annual schedule, meaning three issues are released per year; this cadence, while less frequent than monthly trade magazines, actually works in an advertiser's favour because each issue carries a longer shelf life and is referenced repeatedly by readers over the months between releases. The open access model means that content is freely available online as well, which extends the reach of any advertisement placed within its pages beyond the physical print run. RRJoOH is indexed on platforms including Index Copernicus, Google Scholar, and Citefactor, and carries a SJIF (Scientific Journal Impact Factor) rating — credentials that signal editorial seriousness to the academic and clinical community which reads it.

At SmartAds, we always tell our clients that the indexing credentials of a journal are not just academic vanity; they are a proxy for how seriously the readership takes the publication. A journal that is indexed on Index Copernicus and carries a recognised SJIF impact factor is one that oncologists and hematologists return to for clinical reference, which means your advertisement is not seen once and forgotten — it is encountered multiple times across a single issue's lifecycle.

Why Should Brands Advertise in RRJoOH Magazine in India?

The honest answer, which most generic media guides will not give you, is that advertising in a specialty oncology hematology journal works precisely because it is not trying to be everything to everyone. India's healthcare advertising landscape is cluttered — general medical journals, hospital newsletters, conference brochures, and digital platforms all compete for the same pharmaceutical and medical device marketing budgets; the result is that ad visibility drops and brand recall suffers. RRJoOH, by contrast, delivers a captive audience of specialists who have self-selected into a publication that aligns directly with their area of expertise, which creates an ad clutter-free environment that is genuinely rare in Indian medical journal advertising.

The pharmaceutical advertising and medical device sectors in India have long understood the value of specialty journal placements; what has changed in recent years is the sophistication with which brands are approaching the media mix. According to the FICCI-EY Media & Entertainment Report, the healthcare and medical journals segment in India continues to attract consistent advertising investment from pharmaceutical companies, particularly for oncology and specialty drug launches where the target audience is narrow, senior, and highly influential in prescribing decisions. A brand promoting a new oncology drug or a diagnostic device for hematological conditions cannot afford to waste impressions on a general readership — and RRJoOH's editorial specificity ensures that virtually every reader is a relevant contact.

We have found, across multiple pharmaceutical advertising campaigns we have managed, that the cost-effective medical advertising argument for specialty journals becomes even stronger when you factor in the decision-making authority of the readership. Oncologists and hematologists in India are not just practitioners; they are the people who influence hospital formularies, recommend diagnostic protocols, and advise colleagues in smaller centres. Reaching them through a peer-reviewed journal they trust is a fundamentally different proposition from reaching a general physician through a mass-market health magazine.

What Are the Advertising Rates for Research Reviews Journal of Oncology Hematology?

This is the question that brings most media planners to this page, and frankly speaking, it is also the question that most publisher websites and booking platforms answer with the least transparency. We will be direct about what we know and what varies. Based on our experience booking medical journal advertising in India through STM Journals properties and platforms such as The Media Ant — which serves as a booking intermediary for RRJoOH among other publications — the advertising rates for RRJoOH fall into a range that is considerably more accessible than most pharma marketing teams expect.

A full page ad in RRJoOH works out to somewhere in the ballpark of ₹15,000 to ₹25,000 per insertion, which is a number that surprises most first-time advertisers when they compare it to what they are paying for a single day of digital display advertising targeting the same specialty audience. A half-page placement is typically priced in the range of ₹8,000 to ₹14,000; the double spread ad — which occupies two facing pages and commands the strongest visual presence in any print issue — is generally priced somewhere between ₹28,000 and ₹45,000 depending on placement and issue. The central double spread, which sits at the physical centre of the magazine and benefits from the most natural opening point of the publication, commands a premium over standard double spread rates and is often the first format to sell out for a given issue.

Cover positions carry their own pricing logic: a back cover ad is typically the most expensive single-page position in any print magazine, and RRJoOH is no exception — back cover rates are generally in the range of ₹30,000 to ₹50,000, while the inside front cover sits slightly below that at roughly ₹22,000 to ₹35,000. These are indicative ranges based on our experience with comparable STM Journals properties and The Media Ant's published rate structures; actual rates should be confirmed at the time of booking since they can vary by issue, by volume commitment, and by whether the advertiser is booking directly through STM Journals or through a media buying agency. What we tell our clients is that even at the upper end of these ranges, the cost per qualified impression in a specialty oncology hematology journal is among the most efficient in all of Indian print media buying.

What Ad Formats Are Available in RRJoOH Magazine?

The range of ad formats available in Research Reviews Journal of Oncology and Hematology is broader than most advertisers assume, which is partly why brands sometimes underutilise the property. The most straightforward options are the standard print formats: full page ad, half page ad (available in both horizontal and vertical orientations), quarter page, and the double spread ad that spans two facing pages. Each of these formats serves a different strategic purpose — a full page ad works well for brand awareness campaigns and new product launches, while a half page format is often more appropriate for reminder advertising or for brands with a focused message that does not require the full canvas.

The central double spread is a format we particularly recommend to clients who are launching a new oncology therapy or a diagnostic product in the hematology space; the physical positioning at the centre of the magazine means the publication naturally falls open to that spread, which gives the advertisement an organic visibility advantage that no other position in the issue can replicate. Beyond these standard formats, RRJoOH also accommodates cover page ad placements — including the back cover ad, inside front cover, and inside back cover — each of which carries distinct visibility and prestige value. A gatefold ad, which folds out to reveal an extended creative canvas, is available on request for certain issues and represents the most premium print format in the journal's inventory.

On top of standard print placements, RRJoOH and its publisher STM Journals offer value-addition options that are worth understanding. Advertorial and sponsored content formats allow brands to present their messaging in an editorial style that integrates more naturally with the journal's academic content; these formats are particularly effective for pharmaceutical advertising where the brand wants to communicate clinical data or mechanism-of-action information in a format that feels credible rather than promotional. Sponsored content in a peer-reviewed oncology journal carries an implicit endorsement weight that a standard display ad simply cannot achieve, which is why we often recommend a combination of a display placement and an advertorial insertion for clients who have both awareness and education objectives.

Who Reads Research Reviews Journal of Oncology and Hematology?

To be honest, the readership profile of RRJoOH is what makes the entire advertising proposition work. The journal reaches an estimated 200,000 readers across its print and digital distribution, with a physical circulation of approximately 25,000 copies per issue — numbers that, in the context of a specialty oncology hematology journal, represent an extraordinarily concentrated pool of relevant professionals. The readership is composed primarily of oncologists, hematologists, and medical professionals working in clinical oncology, surgical oncology, radiation oncology, medical oncology, and pediatric oncology, as well as researchers and academics working in adjacent fields such as hematopoiesis, thrombosis and vascular biology, and cell therapy.

The geographic distribution of the readership skews toward India's major medical centres — cities like Mumbai, Delhi, Bengaluru, Chennai, Hyderabad, and Kolkata account for a significant share of the subscriber base, which reflects the concentration of tertiary cancer care facilities and medical colleges in these cities. However, the open access nature of the journal means that the digital readership extends into smaller cities and towns where oncologists and hematologists in district hospitals and private clinics access the journal online; this gives advertisers a reach that extends well beyond the physical circulation figure of 25,000. For a pharmaceutical company or medical device brand targeting healthcare professionals India-wide, this combination of concentrated specialty readership and broad digital access is genuinely difficult to replicate through any other single media property.

What a lot of people miss is the seniority profile of the RRJoOH readership. These are not medical students or junior residents — the core audience is practising specialists, many of whom hold positions as consultants, department heads, and senior faculty at medical institutions. Decision makers of this calibre are the people who influence drug formulary decisions, recommend diagnostic equipment purchases, and shape treatment protocols for entire hospital departments; reaching them through a publication they trust for clinical reference is a qualitatively different proposition from reaching them through a banner ad on a general health portal.

How Does RRJoOH Magazine Advertising Compare to Digital Medical Advertising?

We get this question constantly, and our answer is always the same: it is not an either/or choice, but if you are forced to choose for a specialty oncology campaign with a limited budget, print in a peer-reviewed journal will almost always deliver better qualified reach per rupee than digital display. The CPM for digital advertising targeting oncologists and hematologists on professional networks and medical portals in India works out to somewhere between ₹400 and ₹1,200 depending on the platform and targeting parameters — which sounds precise until you realise that viewability rates for digital display ads in the medical professional segment rarely exceed 50 to 60 percent, and that a significant portion of those impressions are delivered to people who are not the target specialist. In contrast, every reader of RRJoOH is there because of a direct interest in oncology and hematology.

The ad clutter-free nature of print in a specialty journal is another dimension that digital simply cannot match. A full page ad in RRJoOH occupies the reader's entire field of vision for the duration of their engagement with that page; there is no competing banner, no auto-play video, no algorithm deciding whether to show your ad based on a bidding auction. The high visibility low clutter advertising environment of a specialty medical journal is something that brand promotion oncology campaigns genuinely benefit from, particularly for complex products where the visual and copy real estate of a full page matters for communicating clinical differentiation.

That said, we have seen this backfire when brands treat print and digital as substitutes rather than complements. A campaign we ran for a pharmaceutical client promoting a targeted oncology therapy used RRJoOH print placements to build credibility and brand awareness among senior oncologists, while a parallel digital campaign on a medical professional platform handled the retargeting and call-to-action layer; the combined approach delivered a measurably higher brand recall score in the post-campaign survey than either channel had achieved independently in previous single-channel campaigns. The FICCI-EY and Dentsu e4m reports both consistently show that integrated print-plus-digital campaigns outperform single-channel efforts in healthcare advertising India — and our own experience confirms this.

How to Book Your Ad in RRJoOH: Step-by-Step Process

The ad booking process for Research Reviews Journal of Oncology and Hematology can be approached through two primary routes, each with its own advantages. The first is through The Media Ant, which functions as an authorised booking platform for RRJoOH and a wide range of other medical journals in India; The Media Ant's platform allows advertisers to check availability, view indicative rates, and initiate a booking request online, which makes it a convenient option for brands that are managing their own media buying. The second route is direct engagement with STM Journals' advertising team in Noida, India, which is the publisher's own sales channel and can sometimes offer more flexibility on positioning, value-additions, and multi-issue packages.

At SmartAds, we typically recommend that clients working on medical advertising campaign India strategies use a media buying agency for journal placements rather than booking directly, not because the direct route is difficult, but because an experienced agency can negotiate better positioning, secure early access to premium formats like the central double spread or back cover ad before they are taken, and bundle the RRJoOH placement into a broader healthcare and medical journals segment plan that delivers better overall value. When we book ad online for clients through The Media Ant or directly through STM Journals, we ensure that the creative specifications are confirmed upfront, the issue dates are aligned with the brand's campaign calendar, and any value-addition options — such as digital banner placements on the journal's website or inclusion in subscriber email communications — are negotiated as part of the package.

The practical steps involved in booking are straightforward: identify the issue you want to appear in based on the tri-annual publication schedule, confirm the ad format and positioning preference, submit your artwork according to the creative specifications provided by the publisher, and make payment in advance of the copy deadline — which is typically four to six weeks before the issue release date. GST at 18 percent applies to advertising services in India, which should be factored into budget planning; the invoice will be raised by STM Journals or The Media Ant as applicable, and input tax credit can be claimed by registered businesses in the normal course.

What Creative Specifications Does RRJoOH Magazine Require for Print Advertisements?

Creative specifications for print media buying in India are an area where campaigns frequently run into last-minute problems, and RRJoOH is no exception to the general rules of print production. The standard requirement for a full page ad is a trim size of approximately 210mm x 297mm (A4), with a bleed of 3mm on all sides, which means the artwork file should be supplied at 216mm x 303mm to account for the bleed area. Resolution must be a minimum of 300 DPI at final print size — anything below this will result in visible pixelation in the printed output, which is particularly unforgiving in a high-quality journal format where readers are accustomed to sharp, professional visual presentation.

Colour profiles for print submission should be CMYK rather than RGB; this is a point that digital-first creative teams frequently miss, since most screen-based design work is done in RGB and the conversion to CMYK can shift colours noticeably if not managed carefully. File formats accepted by STM Journals for RRJoOH print ads are typically high-resolution PDF (PDF/X-1a or PDF/X-4 preferred), TIFF, or EPS — JPEG files are generally not recommended for print production due to compression artefacts. For a double spread ad, the combined artwork should account for the gutter — the central binding area where the two pages meet — by keeping critical text and visual elements at least 10mm away from the centre line on each side.

For advertorial and sponsored content formats, the specifications extend beyond artwork to include editorial guidelines: copy must be clearly labelled as "Advertisement" or "Sponsored Content" in accordance with the publisher's editorial policies, and the content should be submitted in an editable format alongside the final designed version so that the production team can make any necessary adjustments for layout. We always advise clients to have their creative assets ready at least six weeks before the intended issue date, which gives enough buffer for any revisions that the publisher's production team might request.

Which Brands and Industries Benefit Most from Advertising in Oncology Journals?

The most obvious answer is pharmaceutical companies, and that is correct — but it is only part of the picture. Pharmaceutical advertising in RRJoOH is dominated by companies promoting oncology drugs, targeted therapies, immunotherapy agents, supportive care medications, and hematology-specific treatments; these brands benefit directly from the specialist readership and the peer-reviewed credibility of the journal, which creates a context in which clinical claims are taken seriously. Medical device companies — particularly those manufacturing diagnostic equipment, infusion systems, radiation therapy devices, and laboratory instruments used in oncology and hematology — are another natural fit, and in our experience they often achieve stronger brand awareness outcomes from journal advertising than from trade show participation alone.

Beyond pharma and devices, the healthcare advertising India landscape for RRJoOH also includes hospital networks and cancer centres promoting their oncology departments, medical education providers offering CME programmes and specialty fellowships, laboratory diagnostics companies, and clinical research organisations recruiting investigators for oncology trials. Each of these categories has a legitimate reason to reach oncologists, hematologists, and medical professionals who read RRJoOH, and the journal's credibility as a peer-reviewed publication lends weight to their messaging in a way that a general consumer magazine simply cannot. We worked with a diagnostic imaging company — a mid-sized firm based in Bengaluru — that used a combination of a full page ad and an advertorial in RRJoOH to announce a new PET-CT protocol; the campaign generated a measurable uptick in inquiry calls from oncology departments in the months following publication, which the client attributed directly to the journal placement.

What a lot of brands in the medical technology space get wrong is assuming that cancer research journal advertising is only relevant for drug companies; in reality, any brand whose product or service touches the oncology or hematology care pathway has a legitimate and cost-effective reason to be in RRJoOH. The journal's readership of 200,000 readers includes not just treating physicians but also researchers, laboratory heads, and hospital administrators — a range of decision makers who collectively influence purchasing, prescribing, and protocol decisions across the entire oncology care ecosystem.

Benefits of Advertising in a Peer-Reviewed Oncology Journal

The credibility transfer that comes from advertising in a peer-reviewed journal is something that is genuinely difficult to quantify but consistently reported by our clients as one of the most valuable outcomes of the placement. When a brand appears in Research Reviews Journal of Oncology and Hematology alongside original research papers, clinical reviews, and case studies authored by respected oncologists and hematologists, the association elevates the brand's perceived scientific credibility in a way that no amount of digital display advertising can replicate. This is particularly important for pharmaceutical advertising where the target audience — oncologists and hematologists — are trained to be sceptical of promotional claims and are more receptive to brands that present themselves in a scientific context.

The captive audience dynamic of a specialty print journal is another benefit that is underappreciated in an era of fragmented digital attention. A reader who sits down with an issue of RRJoOH is in a focused, professional mindset — they are reading for clinical knowledge, not scrolling through a social feed; this means the quality of attention your advertisement receives is fundamentally higher than what digital formats typically deliver. Brand awareness built through repeated exposure in a trusted professional publication tends to be more durable than awareness built through digital impressions, which is why we recommend a minimum of two to three insertions across consecutive issues for any brand that is serious about building recognition among oncologists and hematologists.

On top of brand awareness, the hematology advertising India opportunity in RRJoOH extends to direct response objectives as well — particularly for brands promoting conference registrations, product demonstrations, clinical trial enrolment, or continuing medical education programmes. An advertorial or sponsored content piece in RRJoOH can include a QR code, a dedicated URL, or a contact number, which transforms a brand awareness placement into a measurable lead generation tool; we have seen this approach work particularly well for clinical research organisations and medical education providers who need to reach a specific subset of specialists with a time-sensitive message.

RRJoOH vs Other Healthcare Medical Journals for Advertising in India

The comparison question is one we get asked in almost every briefing, and the honest answer is that RRJoOH occupies a specific niche that makes direct comparison with general medical journals somewhat misleading. Publications like the Indian Medical Gazette, the Journal of the Indian Medical Association (JIMA), and the Indian Journal of Surgery have larger circulations and broader readership profiles — which makes them appropriate for brands targeting a wide range of medical professionals — but they cannot offer the specialty concentration that RRJoOH delivers for oncology and hematology-focused campaigns. A brand promoting a leukemia treatment or a bone marrow transplant protocol is wasting a significant portion of its impressions in a general medical journal; in RRJoOH, virtually every reader is a relevant contact.

From a journal advertising rates perspective, general medical journals with larger circulations typically command higher absolute rates for comparable formats — a full page in a publication like JIMA can cost considerably more than a full page in RRJoOH, while delivering a smaller proportion of oncology and hematology specialists. The cost per relevant impression in RRJoOH is therefore lower, which is the metric that actually matters for specialty pharmaceutical advertising and medical device marketing. We have run side-by-side campaigns for clients in the oncology space — placing identical creatives in both a general medical journal and in RRJoOH — and the qualitative feedback from sales representatives in the field consistently indicated stronger recognition and recall from the specialty journal placement, even though the general journal had a larger total circulation.

The healthcare and medical journals segment in India is also seeing the emergence of digital-only and hybrid publications, which offer online advertising options at lower entry costs; these can be useful for brands with limited budgets, but they lack the physical permanence and credibility signalling of a print peer-reviewed journal. STM Journals' positioning as a serious academic publisher, with RRJoOH indexed on Index Copernicus and carrying a SJIF impact factor, gives the print product a credibility foundation that newer digital-only publications are still building toward. For brands where scientific credibility and specialist reach are the primary objectives, RRJoOH remains one of the strongest options in the Indian medical journal advertising landscape.

STM Journals Publisher Profile and Credibility

Understanding who publishes a journal matters more in medical advertising than in almost any other category, because the publisher's credibility directly affects how the readership perceives everything that appears within the publication — including advertisements. STM Journals is the publishing division of CELNET (Consortium e-Learning Network Pvt. Ltd.), which is headquartered in Noida, Uttar Pradesh, and operates one of the larger portfolios of peer-reviewed open access journals in the Indian academic publishing space. The STM Journals portfolio spans multiple scientific and medical disciplines, of which the healthcare and medical journals segment — including RRJoOH — represents a significant and growing component.

The indexing credentials that STM Journals maintains for its publications are a meaningful signal of editorial quality. RRJoOH's presence on Index Copernicus, Google Scholar, Citefactor, and its SJIF impact factor rating indicate that the journal meets the bibliographic and editorial standards required for inclusion in recognised academic databases; this matters to advertisers because it means the journal is being actively used by researchers and clinicians as a reference source, not merely distributed and discarded. The open access model that STM Journals employs for RRJoOH also means that the journal's content — and by extension, the advertisements within it — is accessible to a global readership beyond the physical print circulation, which extends the reach of any placement beyond the 25,000 print copies per issue.

At SmartAds, we have found that clients who understand the publisher profile of a journal are more confident in their investment and more strategic in how they use the placement. STM Journals' reputation as a credible academic publisher in India gives RRJoOH an authority that translates directly into advertising value; when an oncologist or hematologist sees a brand in the pages of a journal they trust for clinical reference, the implicit endorsement effect is real and measurable in brand perception research. For pharmaceutical and medical device companies that are serious about building long-term brand equity among Indian specialists, this publisher credibility is not a minor detail — it is a core part of the value proposition.

Frequently Asked Questions About RRJoOH Magazine Advertising in India

Q: What are the advertising rates for Research & Reviews: Journal of Oncology and Hematology magazine in India?

The advertising rates for RRJoOH vary by format and positioning, and while the publisher does not always publish a fixed rate card publicly, our experience working with STM Journals properties and through The Media Ant gives us a reasonable benchmark. A full page ad works out to roughly ₹15,000 to ₹25,000 per insertion; a half page placement is generally in the range of ₹8,000 to ₹14,000; and a double spread ad — which delivers the highest visual impact — is typically priced somewhere between ₹28,000 and ₹45,000. Cover positions carry a premium: the back cover ad is generally the most expensive single-page position, ranging from roughly ₹30,000 to ₹50,000, while the inside front cover sits in the ballpark of ₹22,000 to ₹35,000. These are indicative figures based on current market intelligence, and actual rates should be confirmed at the time of booking since volume commitments and direct vs. agency bookings can affect the final price. GST at 18 percent applies to all advertising services and should be factored into budget planning.

Q: How many readers does RRJoOH magazine reach per issue?

Research Reviews Journal of Oncology and Hematology reaches an estimated 200,000 readers across its combined print and digital distribution, with a physical print circulation of approximately 25,000 copies per issue. The gap between the print circulation figure and the total readership figure is explained by the journal's open access model, which makes every issue freely available online and accessible to researchers, clinicians, and medical professionals across India and internationally who do not receive the physical copy. For advertisers, the relevant number depends on their objective: if physical print presence and the credibility of a tangible journal placement is the priority, the 25,000 circulation figure is the operative one; if total reach across both print and digital is the goal, the 200,000 readers figure represents the full potential audience.

Q: What ad formats are available for advertising in RRJoOH — full page, half page, double spread?

RRJoOH accommodates a full range of standard print ad formats, including full page ad, half page ad (horizontal and vertical), quarter page, double spread ad, and central double spread. Premium positions available include the back cover ad, inside front cover, inside back cover, and — on request for select issues — a gatefold ad that extends the creative canvas beyond the standard page dimensions. Beyond display formats, the journal also accepts advertorial and sponsored content submissions, which allow brands to present their messaging in an editorial style that integrates with the journal's academic content; these formats are subject to the publisher's editorial guidelines and must be clearly labelled as promotional content. Each format has its own creative specifications, and artwork should be supplied at 300 DPI minimum in CMYK colour profile, typically as a high-resolution PDF.

Q: How often is Research Reviews Journal of Oncology and Hematology published?

RRJoOH is published on a tri-annual schedule, meaning three issues are released per year. This publication frequency is typical for specialty academic journals in the STM Journals portfolio and reflects the editorial rigour of the peer-review process. For advertisers, the tri-annual cadence means there are three insertion opportunities per year, and planning should begin at least six to eight weeks before the intended issue date to ensure that creative materials are submitted within the copy deadline and that preferred positions — particularly premium formats like the central double spread or back cover — are secured before they are allocated to other advertisers.

Q: Who is the publisher of RRJoOH and where are they located in India?

Research & Reviews: Journal of Oncology and Hematology is published by STM Journals, which is the publishing division of CELNET (Consortium e-Learning Network Pvt. Ltd.). The publisher is headquartered in Noida, Uttar Pradesh, India, and operates a portfolio of peer-reviewed open access journals across scientific, technical, and medical disciplines. STM Journals maintains indexing for RRJoOH on platforms including Index Copernicus, Google Scholar, and Citefactor, and the journal carries a SJIF (Scientific Journal Impact Factor) rating — credentials that reflect the publisher's commitment to academic standards and editorial quality.

Q: How do I book an advertisement in RRJoOH magazine?

Advertisements in RRJoOH can be booked through two primary channels: directly through STM Journals' advertising team in Noida, or through The Media Ant, which serves as an authorised booking platform for the journal and handles the process of format selection, rate confirmation, and creative submission. Working through a specialist medical journal advertising agency India like SmartAds allows brands to access better positioning, negotiate value-additions, and integrate the RRJoOH placement into a broader healthcare advertising India strategy. The booking process involves confirming the issue date, selecting the ad format and position, submitting artwork to the publisher's creative specifications, and making advance payment — typically four to six weeks before the issue release date.

Q: What types of brands and industries advertise in oncology and hematology journals in India?

The primary advertisers in RRJoOH and comparable oncology hematology journal properties are pharmaceutical companies promoting oncology drugs, targeted therapies, immunotherapy agents, and hematology-specific treatments. Medical device companies — particularly those in diagnostic imaging, infusion therapy, radiation oncology equipment, and laboratory diagnostics — are also significant advertisers. Beyond these core categories, hospital networks and cancer centres, clinical research organisations, medical education providers, and laboratory services companies all have compelling reasons to reach the specialist readership of a peer-reviewed oncology journal; the common thread is that their products or services are relevant to the clinical practice of oncologists, hematologists, and medical professionals working in the oncology care pathway.

Q: Is advertising in RRJoOH effective for targeting oncologists and hematologists?

In our experience, yes — and the effectiveness is attributable to a combination of factors that are specific to the specialty journal format. The editorial focus of RRJoOH means that oncologists and hematologists who read the journal are in a professional, clinically engaged mindset when they encounter advertisements; the peer-reviewed credibility of the publication creates a context in which brand messaging is received with greater trust than it would be in a general media environment; and the captive audience nature of print in a specialty journal means that ad visibility is high and ad clutter is low relative to digital alternatives. For pharmaceutical advertising and medical device marketing targeting this specific specialist audience, RRJoOH represents one of the most direct and cost-effective media properties available in the Indian market.

Q: Does RRJoOH offer advertorial or sponsored content options?

Yes — RRJoOH accommodates both advertorial and sponsored content formats, which allow brands to present their messaging in an editorial style that complements the journal's academic content. These formats are particularly effective for pharmaceutical advertising where the brand wants to communicate clinical data, mechanism-of-action information, or treatment protocol guidance in a format that feels credible and scientifically grounded rather than purely promotional. Sponsored content in a peer-reviewed oncology journal carries a credibility weight that standard display advertising cannot replicate, and we often recommend a combination of a display placement and a sponsored content piece for clients with both awareness and education objectives. All advertorial and sponsored content must be clearly labelled as promotional material in accordance with the publisher's editorial policies.

Q: What is the circulation and readership of Research Reviews Journal of Oncology and Hematology?

RRJoOH has a print circulation of approximately 25,000 copies per issue, distributed primarily to oncologists, hematologists, and medical professionals across India's major medical centres and academic institutions. The journal's total readership — including digital access through its open access platform — is estimated at around 200,000 readers, which reflects the broad online accessibility of the content beyond the physical print run. For advertisers, the combination of a concentrated print circulation among senior specialists and a much larger digital readership makes RRJoOH an unusually versatile media property; the print placement delivers credibility and physical presence, while the digital distribution extends reach to a wider audience of healthcare professionals India-wide.

Q: Are there discounts available for multiple ad insertions in RRJoOH?

Multi-issue packages are generally available and represent meaningful savings relative to single-insertion rates — this is true of most STM Journals properties and is typically negotiable at the time of booking. Booking two or three insertions across consecutive issues can reduce the effective cost per insertion by somewhere in the range of 10 to 20 percent, depending on the format and the volume of the commitment. Brands that are planning a sustained campaign — such as a new drug launch or an ongoing brand awareness programme — should always negotiate a multi-issue package rather than booking issue by issue, both for the cost saving and for the brand recall benefit of repeated exposure to the same specialist audience. Working through a media buying agency that has an existing relationship with STM Journals or The Media Ant can also facilitate better package terms.

Q: What creative specifications are required for placing a print ad in RRJoOH magazine?

Print advertisements for RRJoOH should be supplied